Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2025)

Historic FCF Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 21.86%.

  • Catalyst Pharmaceuticals' FCF Margin fell 345600.0% to 21.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.56%, marking a year-over-year decrease of 80800.0%. This contributed to the annual value of 48.65% for FY2024, which is 126500.0% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its FCF Margin stood at 21.86% for Q3 2025, which was down 345600.0% from 48.63% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' FCF Margin ranged from a high of 72.15% in Q3 2022 and a low of 9.61% during Q1 2021
  • Over the past 5 years, Catalyst Pharmaceuticals' median FCF Margin value was 48.63% (recorded in 2025), while the average stood at 42.78%.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' FCF Margin surged by 213700bps in 2024 and then plummeted by -345600bps in 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' FCF Margin (Quarter) stood at 49.95% in 2021, then surged by 32bps to 65.96% in 2022, then fell by -24bps to 50.25% in 2023, then fell by -1bps to 49.91% in 2024, then plummeted by -56bps to 21.86% in 2025.
  • Its FCF Margin was 21.86% in Q3 2025, compared to 48.63% in Q2 2025 and 42.46% in Q1 2025.